[Detecting multi-drug resistance of bladder cancer for the intravesical chemotherapy]

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Bladder cancer presents a significant challenge, often necessitating intravesical chemotherapy.
• Multi-drug resistance (MDR) is a major obstacle to effective bladder cancer treatment.
• Identifying resistance mechanisms is crucial for optimizing therapeutic strategies.

Purpose of the Study:

• To investigate the expression of key proteins associated with multi-drug resistance (MDR) in human bladder cancer cells.
• To evaluate the potential role of these proteins in resistance to intravesical chemotherapy.
• To provide insights for selecting appropriate chemotherapeutic agents.

Main Methods:

• Immunohistochemical staining was employed to detect protein expression in 44 human bladder cancer tissue samples.
• The study focused on the expression levels of P-glycoprotein (P-gp), glutathione S-transferase pi (GST-pi), and topoisomerase II (TOPO-II).

Main Results:

• P-glycoprotein (P-gp) showed higher expression in 54.5% of the cases analyzed.
• Glutathione S-transferase pi (GST-pi) exhibited no or low expression in 65.9% of cases.
• Topoisomerase II (TOPO-II) displayed higher expression in 29.5% and lower expression in 65.9% of cases.

Conclusions:

• The differential expression of P-gp, GST-pi, and TOPO-II suggests their involvement in bladder cancer's multi-drug resistance.
• Assessing these MDR-associated factors in bladder cancer cells can aid in the personalized selection of drugs for intravesical chemotherapy.
• This approach may enhance treatment efficacy and patient outcomes.